Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2315-2325

  Rochau, Ursula ^a,b   Sroczynski, Gaby ^a   Wolf, Dominik ^c,d   Schmidt, Stefan ^c   Jahn, Beate ^a   Kluibenschaedl, Martina ^a   Conrads Frank, Annette ^a   Stenehjem, David ^e,f   Brixner, Diana ^a,b,e   Radich, Jerald ^g   Gastl, Günther ^c   Siebert, Uwe ^a,b,h,i  

^a UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^b Oncotyrol   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g USA   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chronic myeloid leukemia; cost eff ectiveness analysis; decision analysis; decision analytic model; health economic modeling; tyrosine kinase inhibitors

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG TREATMENT FAILURE; DRUG UTILIZATION; FEMALE; GRAFT VERSUS HOST REACTION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH STATUS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; AUSTRIA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MARKOV CHAIN; OUTCOME ASSESSMENT; REGISTER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH CARE COSTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES;

EID: 84943395388     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.982635     Document Type: Article

References (80)

1. Druker BJ, Guilhot F, OBrien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. OBrien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
4. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
5. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
6. National Comprehensive Cancer Network (NCCN). [Internet]. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic myelogeneous leukemia. Version 2.2014. United States. 2013. Available from: www.nccn.org/professionals/physician-gls/pdf/cml.pdf.1-91
7. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 409-429.
8. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium-the just price. J Clin Oncol 2013; 31: 3600-3604.
9. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013; 119: 3900-3902.
10. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12: 933-980.
11. Ludwig Boltzmann Institut. [Internet]. LBI Horizon Scanning Projekt. Vienna; 2008. Available from: http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie
12. Gesundheit Österreich GmbH, BIQG, HTA-Arbeitsgruppe. Nationale HTA-Strategie. Version 1.0. Im Auftrag des Bundesministeriums für Gesundheit. 2009; 1: 4-5.
13. Fröschl B, Bornschein B, Brunner-Ziegler S, et al. Methodenhandbuch für Health Technology Assessment Version 1.2012. Im Auftrag des Bundesministeriums für Gesundheit. 2012; 1.
14. Rochau U, Sroczynski G, Wolf D, et al. Medical decision analysis for first-line therapy of chronic myeloid leukemia. Leuk Lymphoma 2014; 55: 1758-1767.
15. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
16. Weinstein MC. Decision rules for incremental cost-effectiveness analysis. In: Jones AM., editor. The Elgar companion to health economics. Cheltenham, UK: Edward Elgar Publishing Ltd; 2006. pp 469-478.
17. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14: 259-265.
18. Phillips C. What is cost effectiveness? In: Health Economics. 2nd ed. 2009. Available from: www.whatisseries.co.uk.
19. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press; 2005.
20. Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health 2012; 15: 796-803.
21. Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health 2012; 15: 812-820.
22. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013; 16: e1-e5.
23. OeGHO. [Internet]. The Austrian CML-Registry. 2014. Available from: www.cml-registry.com/login-en.xhtml
24. Schmidt S, Wolf D, Thaler J, et al. First annual report of the Austrian CML registry. Wien Klin Wochenschr 2010; 122: 558-566.
25. Statistik Austria. [Internet]. Sterbetafeln. 2012. Available from: http://www.statistik.at/web-de/statistiken/bevoelkerung/sterbetafeln/index.html
26. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212.
27. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-3546.
28. Pavey T, Hoyle M, Ciani O, et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess 2012; 16:iii-iv, 1-277.
29. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7):vi i72-vi i77.
30. AGfSZT. ASCTR (Austrian Stem Cell Transplantation Registry) 2011. Presented at: EBMT Meeting, April 2012, Geneva.
31. Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
32. Auberger J, Clausen J, Kircher B, et al. Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients. Eur J Haematol 2011; 87: 531-538.
33. Devergie A. Graft versus host disease. In: Apperley J, Carreras E, Gluckman E, et al., editors. ESH-EBMT handbook on haemopoietic stem cell transplantation. [Internet]. 2008; pp 219-235. Available from: www.ebmt.org
34. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
35. Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005; 23: 515-526.
36. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004; 101: 2574-2583.
37. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010; 26: 183-191.
38. Österreichische Apotheker-Verlagsgesellschaft m.b.H. [Internet]. Warenverzeichnis. Austria. 2012. Available from: http://warenverzeichnis.apoverlag.at/
39. Bundesministerium für Gesundheit. [Internet]. Leistung sorientierte Krankenanstaltenfinanzierung (LKF). Austria. 2013. Available from: http://bmg.gv.at/home/Schwerpunkte/Krankenanstalten/LKF-Leistungsorientierte-Krankenanstaltenfinanzierung/
40. Bundesministerium für Gesundheit. [Internet]. Programmpakete KDok für landesgesundheitsfondsfinanzierte Krankenanstalten. Austria. 2012. Available from: http://bmg.gv.at/home/Schwerpunkte/Gesundheitssystem-Qualitaetssicherung/Dokumentation/Programmpakete-KDok-fuer-landesgesundheitsfondsfinanzierte-Krankenanstalten
41. Hauptverband der österreichischen Sozialversicherungsträger. [Internet]. Verfahrensordnung zur Herausgabe des Erstattungskodex nach § 351g ASVG-VO-EKO. Austria. 2004. Available from: http://www.aphar.at/pdfs/avsv-2004-047.pdf
42. Apotheke adhoc. European Medicines Agency. [Internet]. Glivec wird generisch. Berlin. 27 Feb 2013. Available from: www.apotheke-adhoc.de/nachrichten/nachricht-detail/ema-imatinib-wird-generisc/?no-cache=1&L=0
43. Drug.com. [Internet]. Generic Sprycel availability. United States. 2014. Available from: www.drugs.com/availability/generic-sprycel.html
44. Drug.com. [Internet]. Generic Tasigna availability. United States. 2014. Available from: www.drugs.com/availability/generic-tasigna.html
45. Briggs AH, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press; 2006.
46. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 2012; 15: 835-842.
47. Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500.
48. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997; 127: 1080-1088.
49. National Institute for Health and Care Excellence (NICE). [Internet]. Process and methods guides. Guide to the methods of technology appraisal 2013. UK. 2013. Available from: http://www.nice.org.uk/article/PMG9/1-93
50. Raad voor de Volksgezondheid en Zorg aan de minister van Volksgezondheid. [Internet]. Zinnige en duurzame zorg. The Netherlands. 2006. Available from: www.rvz.net/uploads/docs/Advies-Zinnige-en-duurzame-zorg.pdf.1-112
51. Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib-a Swedish model application. Acta Oncol 2010; 49: 851-858.
52. Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or-intolerant chronic phase chronic myeloid leukemia. Value Health 2011; 14: 1057-1067.
53. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009; 360: 626-633.
54. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
55. Wise J. NICE backs leukaemia drug after manufacturer drops price. BMJ 2012; 344: e2274.
56. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533-539.
57. Center for the Evaluation of Value and Risk in Health. [Internet]. The Cost-Effectiveness Analysis Registry. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. United States. 2014. Available from: www.cearegistry.org
58. Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 225-234.
59. Woods B, Hawkins N, Dunlop W, et al. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 2012; 15: 759-770.
60. Lu L, Peters J, Roome C, et al. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. Int J Technol Assess Health Care 2012; 28: 241-248.
61. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
62. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
63. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95: 232-240.
64. Kantarjian H, Giles F, Bhalla K, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112 (Suppl. 1): Abstract 3238.
65. Kantarjian H, OBrien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109: 1556-1560.
66. Cervantes F, Lopez-Guillermo A, Bosch F, et al. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996; 57: 286-291.
67. Niederösterreichischer Gesundheits-und Sozialfonds (NÖGUS). Ambulanzkatalog. 2012.
68. Tiroler Gesundheitsfonds (TGF). Ambulanzabrechnungskatalog. 2012.
69. Burgenländische Gebietskrankenkasse (BGKK). Zusatzvere inbarung 2010/2011/2012. 2012.
70. Kärntner Gebietskrankenkasse (KGKK). Honorartarif. 2012.
71. Niederösterreichische Gebietskrankenkasse (NÖGKK). Honora rordnung. 2011.
72. Oberösterreichische Gebietskrankenkasse (OÖGKK). Arbeits behelf Honorarordnung für Ärzte für Allgemeinmedizin und Fachärzte. 2010.
73. Salzburger Gebietskrankenkasse (SGKK). Honorartarif zum Gesamtvertrag. 2012.
74. Steirische Gebiertskrankenkasse (StGKK). Honorarverordnung für Einzelverträge und Fachärzte. 2011.
75. Tiroler Gebietskrankenkasse (TGKK). Honorarordnung für Ärzte und Allgemeinmedizin und Fachärzte. 2010.
76. Vorarlberger Gebietskrankenkasse (VGKK). Honorartariffür Vorarlberg, gültig ab 01.01.2012. 2012.
77. Wiener Gebietskrankenkasse (WGKK). Tarif für allgemeine Vertragsfachärzte. 2012.
78. Kattan MW. Encyclopedia of medical decision making. Thousand Oaks, CA: SAGE Publications; 2009.
79. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs. Cambridge: Cambridge University Press; 1993.
80. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459-467.